A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA

BACKGROUND/OBJECTIVE: Baricitinib is a selective and reversible Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor inhibitors (TNFis) and has...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehler, Elizabeth, Boytsov, Natalie, Nicolay, Claudia, Herrera-Restrepo, Oscar, Kowal, Stacey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081656/
https://www.ncbi.nlm.nih.gov/pubmed/31452079
http://dx.doi.org/10.1007/s40273-019-00829-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081656/
https://www.ncbi.nlm.nih.gov/pubmed/31452079
http://dx.doi.org/10.1007/s40273-019-00829-x

Ejemplares similares